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ABSTRACT
A broad review is given of the impact of big data on various aspects of inves-
tigation. There is some but not total emphasis on issues in epidemiological
research.
1 Introduction
Over the last 125 years computational techniques have evolved from slide rule
and log tables, through hand operated machines like the Brunsviga, to electric
desk-top machines, and from them to modern computers, at first complex to
use and limited in scope and then to the ever expanding modern ubiquitous
version. The development of statistical technique and theory over that time
has mirrored and been strongly influenced by that growth in computer power
and availability.
Big data have been around a long time, for example in population cen-
suses. In an engineering context, paper traces recorded such properties as
the stress at various points in an aircraft wing during flight. In a manufac-
turing context, the mass per unit length of textile yarn was recorded. These
examples produced very large amounts of data for visual inspection, but
in the past suitable for quantitative analysis at most on a sampling basis.
Three questions that characterize today’s big data are largely absent from
these earlier contexts. In outline the questions are: Are the data relevant
for the purpose of the investigation? Is the data quality adequate for its in-
tended purpose? Is the detailed statistical analysis appropriate, in particular
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is the assessment of the precision of the conclusions seriously overoptimistic?
Sometimes the first two aspects may be inverted: the data are available, for
what are they useful? We comment on these issues largely, but not entirely,
from an epidemiological perspective.
In an epidemiological context, large data sets with many individuals arise
from routinely collected medical records, from cohorts assembled with a de-
fined objective, and from registries of patients with specific conditions. Some
large population-based studies are of mixed type, in that they are cohorts
with a purpose-built baseline data set augmented by linkage to routinely col-
lected records or registries. Many aspects of study design and analysis are
common to large and not-so-large sets of data but the achievement of high
quality in large sets of data may be a particular challenge.
There are a number of conceptual aspects of a study all of which may
have statistical implications. These are: Question formulation; Choice of
study population; Study design; Metrology; Data collection; Monitoring and
quality control; Data analysis; Presentation of conclusions; Interpretation.
When big data are involved all of these may raise special features. Here we
concentrate largely but not entirely on the aspects prior to data analysis.
2 Some types of study
In a health context there are several ways in which big data may arise.
One is via routine collection in so-called electronic-health (‘e-health’) record
databases. In the UK the Clinical Practice Research Database (CPRD)
(Herrett et al, 2015) has data on over 11 million patients from over 600
general practices. Information is recorded on individuals receiving normal
care and the resulting data are sometimes described as ‘found’ data. Because
the information on a patient arises from visits to a doctor the amount of data
per patient is itself informative.
Another source of big data is patient registries with information on in-
dividuals with a specific condition, such as the UK and US cystic fibrosis
patient registries. Data are more specific to the condition in question and
the acquisition may include elements of both ‘design’ and ‘observation’. For
example, the US Cystic Fibrosis Foundation Patient Registry collects data
from patients’ visits to their care team, both routine and not, via a stan-
dardized approach using a web-based portal (Knapp et al, 2016). The UK
Cystic Fibrosis registry obtains data annually at a visit arranged specifically
to acquire data (Taylor-Robinson et al, 2017).
Other large data sets arise from cohorts recruited and followed with spe-
cific questions in mind, although may later be expanded to enable other in-
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vestigations. An example is the Million Women Study (The Million Women
Study Collaborative Group, 1999), the original primary aim of which was to
study the relationship between use of hormone replacement therapy and the
risk of breast cancer, and the European Prospective Investigation into Can-
cer and Nutrition, which aimed to study associations between diet, lifestyle
and environmental factors, and the incidence of chronic diseases.
Many large-scale studies are designed to answer a wide-ranging set of
questions over a period, allowing for new questions to emerge over time,
rather than to address one or two specific pre-specified issues. An example in
another field is the massive investigations in particle physics at CERN; these
focused initially on finding the Higgs boson (ATLAS collaboration, 2012)
but by the time that issue was resolved other wide-ranging searches for “new
physics” were in progress. Developments in astrophysics raise special issues.
Examples in health include the China Kadoorie Biobank (Chen et al, 2005,
2011) and the UK Biobank (Collins, 2012), which obtain information across
many domains thus allowing wide-ranging investigation. Biological samples
collected in these studies also enable generating new data on these cohorts,
perhaps as part of a nested case-control or case-subcohort study (Keogh and
Cox, 2014).
Many large datasets consist of several datasets, each collected separately,
such as consortia in genetic epidemiology, for example CIMBA (Chenevix-
Trench et al, 2007).
3 Coverage and representativeness
Large datasets may not represent the underlying population of interest and
sheer largeness of a dataset clearly does not imply that population param-
eters, such as prevalences or absolute risks, can be estimated without bias.
However, lack of representativeness is less of a concern when the focus is on
estimation of relative associations, for example risk ratios. Studies may also
be designed not to be representative of the underlying population but using
stratified sampling to capture a wide variety of participant characteristics.
Registries of rare diseases are more likely to be representative of the relevant
population. For example, the UK Cystic Fibrosis Registry contains data on
nearly all individuals with Cystic Fibrosis in the UK.
There is often some self-selection of participants of large cohort studies.
Self-selection is not necessarily a problem for investigation of associations
and dependences. However, biased estimates of associations of interest may
arise if factors affecting selection are not accounted for by analysis, and es-
pecially if there are important factors affecting selection that are unknown
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or unmeasured and yet associated with the main factors under investigation.
A particular advantage of large data sets is that they can cover a num-
ber of underlying subpopulations with particular features, e.g. age, ethnic-
ity and socioeconomic status, which enable investigations of the stability of
conclusions across different groups. The opt-out nature of electronic health
databases such as the CPRD mean that patients with a wider range of charac-
teristics are captured relative to studies in which participants opt in (Herrett
et al, 2015). Issues of representativeness arise also in sociological investi-
gations, for example of the impact of parental social class on aspects of the
childrens’ life (Goldthorpe, 2016). In such work formal probabilistically based
sampling techniques are more likely to be employed but response rates are
often so low that the formal justification of inference to the target population
may be unconvincing. Instead justification of conclusions about the target
population is, as in the epidemiological context, more firmly based on show-
ing the stability of the conclusions, that is absence of statistical interaction
with major features.
4 Metrology
Metrology, that is issues of measurement, is central to progress in many
fields. ‘Big data’ often comprise data that are not just large in volume
but also complex. Just a few instances in a biomedical context are data
obtained from genotyping arrays, platforms for proteomics, metabolomics
and transcriptomics, accelerometers to measure sleep and physical activity,
devices that measure physical features, brain and other body scans, and
geocoded air pollution data. New fields of study may be opened up by
reliable methods of measurement becoming available for relatively routine
use.
However elaborate the method or instrument employed some key princi-
ples remain, some of them inherited from the early work at national orga-
nizations such as the National Bureau of Standards in Washington DC, the
National Physical Laboratory in the UK, and also by organizations specifi-
cally concerned with implementation of standards. Aspects of the monitoring
of industrial quality and sampling inspection were intensively studied from
the 1930s onwards and extended to such topics as the auditing of accounts by
monetary unit sampling. The much more elaborate largely automated meth-
ods now in common use raise essentially the same issues of the standardiza-
tion of different instruments and of checks of their stability and detection of
occasional malfunction. If, as is sometimes the case, internal computation is
involved this too may require monitoring. When, as in the interpretation of
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X-rays, an element of subjective judgement is involved research investigations
may need randomization to ensure concealment and absence of measurement
bias. It is unclear to what extent the expertise and experience of the earlier
work has been continued and extended.
An important consideration is the design of questionnaires and interview-
based instruments. Device data may be collected to replace self-reported
information which may be less accurate and have potential for bias; for ex-
ample sleep and physical activity data suggest that the amount of time spent
in these states as perceived by the study individual may differ substantially
from data measured using accelerometers. Another purpose is to collect sev-
eral ‘layers’ of data on the same underlying process at various stages of the
causal chain to gain more detailed insight on the process, for example ge-
nomic and downstream transcriptomic and proteomic data. Collecting such
layers of data also opens new possibilities in the way that the data are used,
for example in an instrumental variables approach. Genetic data are often
used combined with epidemiological exposure data in Mendelian randomiza-
tion analyses which help assess whether an observed association may reflect
a potentially causal relationship, although the assumptions involved are not
always easily checked.
In some cases error is introduced in the process of generating the data
themselves. For the types of data discussed above complex pre-processing is
required before analysis involving important decisions. For example, imaging
data and accelerometer data may be pre-processed in various ways before
different features are extracted to be used in downstream analysis. Spatial
air pollution, temperature or humidity data may be assigned to individuals
using different methods.
New ways of collecting data are sometimes used, such as data being col-
lected by ‘lay’ persons. An example is ‘crowd sourcing’ where people help
generate data; another situation is when individuals collect data about them-
selves, such as symptom monitoring, commonly using a phone application,
which enables individuals to report their symptoms in their natural environ-
ment rather than in a doctor’s office and at more frequent times. There may
be different issues related to the collection, quality check and analysis of such
data.
5 Data quality
A sense that having data on a very large number of individuals renders
problems of study design or data quality such as errors of measurement and
missing data unimportant is usually misguided. One consequence of nomi-
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nally small standard errors of estimation may be to make potential biases of
more concern.
Routinely collected data may allow addressing many different questions.
However, because the data are not collected for a specific purpose they may
be subject to particular issues of data quality. For example, the information
recorded in electronic health records by different doctors may vary in detail
and accuracy. Data may be missing for a variety of reasons in such records,
for reasons likely to depend on observed and unobserved patient character-
istics. The CPRD encourages data quality via an incentive scheme (Herrett
et al, 2015). The data recorded rely on measures used in routine care, which
may not be the gold standard or the best for addressing a particular question.
Greater control over some aspects of data collection and quality is possible in
cohorts assembled for research. An example with high quality of data collec-
tion is the China Kadoorie Biobank, with data collection using streamlined
procedures implemented by trained staff, built-in quality control checks, e.g.
for implausible values, a quality control survey of a subset of participants,
and regular monitoring of newly collected data. Outcome data obtained via
linkage with health insurance records, disease and death registries are en-
hanced by reviews of residential records and local visits. Event adjudication
is carried out for major outcomes to minimise misclassification and obtain
more details. Statistical sampling inspection and quality control have long
histories in industrial contexts starting from the early 1930s and extending
into such fields as the auditing of accounts.
The availability of large numbers of variables in routinely collected data
makes adjustment for large numbers of potential confounders possible; this
brings its own challenges for analysis and special methods have been de-
veloped for adjusting for large numbers of confounders (Schneeweiss et al,
2009). Cohorts, such as population-based epidemiological studies designed
to investigate a large number of exposures and outcomes, may not record very
detailed information on all domains and may therefore lack detailed variables
for some investigations needed either as exposures, outcomes or confounders.
Data sets with health information are often linked to other data, such as
from hospital episodes. Biases can be introduced in such linkage, in particu-
lar when the different databases do not contain the same unique individual
identifiers (Harron et al, 2014).
When data are derived from device measurements, the data produced
must be thoroughly checked for various types of error that may arise. In
some specific fields there are well established quality control and assurance
procedures, such as in genetic epidemiology.
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6 Analysis and precision
Details of analysis will not be discussed in this paper. A broad strategic
issue particularly prominent for big data is the contrast between analysing
the data in relatively compact subsections aiming for an ultimate synthesis
versus a one-step analysis involving the fitting of a relatively complex model.
The former may be much slower but often more secure.
Conventional statistical thinking emphasizes, often over-emphasizes, the
underpinning of statistical analysis by formal probability models. By contrast
some approaches, such as neural nets for unravelling complex dependences,
are solely algorithmic.
Most although not all relatively standard statistical procedures produce,
after due precaution against anomalies, estimates with standard errors in-
versely proportional to the square root of sample size. For big data these
standard errors are thus likely to be extremely small. Yet, to take just one
example, the notion that the difference in mean survival times comparing
two treatment regimens can be defined and estimated meaningfully with
very high precision is unconvincing.
In fact there is evidence from many fields that when data are examined
with a broad horizon standard errors may decrease inversely as a smaller
power of sample size, for example as the one-quarter power. Examples in-
clude hydrology, the so-called Hurst effect based on studies of the River Nile,
agriculture, error versus plot size, and turbulence. For the direct implica-
tions for statistical analysis, treated theoretically, see Cox (2016). Thus,
whereas in some contexts big data may decrease the importance of precision
assessment, in others special care may be needed.
There are also computational issues, in that when data are sufficiently
complex and multiple steps of relatively standard processing is required, pre-
specified schemes of analysis are often used. This may be useful in mak-
ing analysis more efficient and reproducible and in minimising human er-
ror. Sometimes, however, issues that arise in the middle of the process may
be overlooked if there is not sufficient diagnostic information produced and
sometimes inferior analyse s may result.
There are also issues to be considered in the analysis of particular types
of data. In electronic health records and in some patient registries, data are
recorded each time the patient has contact with their health care system. A
consequence of this is that data are recorded more frequently for patients with
poorer health. Informative observation of participants presents challenges
for statistical analyses making use of longitudinal measurements, and could
result in biased inferences if not handled correctly.
Another particular situation has a very large number of variables of the
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same type, such as genomic variables, possibly on a relatively small number of
individuals, in which if variables are considered simultaneously, interpretation
relies on an assumed sparsity of effects (Tibshirani, 1996; Cox and Battey,
2017).
7 Concluding remarks
Big data enable investigations to be conducted and reliable conclusions to be
drawn that would otherwise be difficult or impossible. An example is their
use in pharmacoepidemiology to evaluate treatment effects (Smeeth et al,
2009; Hernan & Robins, 2016).
We have highlighted some of the challenges that arise in the use of big
data. One main theme has been to emphasise the potential for overconfi-
dence in results obtained from analyses of large data sets, due to superficially
highly precise but potentially biased estimates, or due to under-estimated
standard errors. The size of the data does not remove the need for appro-
priate study design and statistical analysis (e.g. Welch et al, 2014, Lin et al,
2004, Pullenayegum & Lim, 2016). The potential impact of unobserved and
unaccounted-for dependencies must not be ignored.
We have focused primarily on big data in the biomedical field. Even
within that field there are many sources of big data that we have not men-
tioned. Each may present special challenges and opportunities.
In summary, while the availability of big data offers many possibilities for
improved understanding, the need for careful and productive use of statistical
concepts is pervasive and raises many challenges.
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